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Abstract
Background: Disproportionate regulation of health and medical research contributes to research waste. Better
understanding of exemptions of research from ethics review in different jurisdictions may help to guide
modification of review processes and reduce research waste. Our aim was to identify examples of low-risk human
health and medical research exempt from ethics reviews in Australia, the United Kingdom, the United States and
the Netherlands.
Methods: We examined documents providing national guidance on research ethics in each country, including
those authored by the National Health and Medical Research Council (Australia), National Health Service (United
Kingdom), the Office for Human Research Protections (United States) and the Central Committee on Research
Involving Humans (the Netherlands). Examples and types of research projects exempt from ethics reviews were
identified, and similar examples and types were grouped together.
Results: Nine categories of research were exempt from ethics reviews across the four countries; these were existing
data or specimen, questionnaire or survey, interview, post-marketing study, evaluation of public benefit or service
programme, randomised controlled trials, research with staff in their professional role, audit and service evaluation,
and other exemptions. Existing non-identifiable data and specimens were exempt in all countries. Four categories –
evaluation of public benefit or service programme, randomised controlled trials, research with staff in their
professional role, and audit and service evaluation – were exempted by one country each. The remaining
categories were exempted by two or three countries.
Conclusions: Examples and types of research exempt from research ethics reviews varied considerably. Given the
considerable costs and burdens on researchers and ethics committees, it would be worthwhile to develop and
provide clearer guidance on exemptions, illustrated with examples, with transparent underpinning rationales.
Keywords: Research ethics, research committees, waste in research, low-risk research, exemption, international
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Introduction
In 2009, it was estimated that 85% of research funding
for biomedical science (including clinical, health services
and basic science) research is avoidably wasted, at an an-
nual cost of approximately $170 billion [1–3]. This waste
is due to the failure to ask questions relevant to users of
research, appropriately design, conduct and analyse re-
search, efficiently regulate and manage research, produce
accessible and full research reports, and produce un-
biased and useable research reports [2]. The inefficient
regulation and management of research has been argued
to manifest itself in the hyper-regulation of research,
that is, regulation, governance and management, that are
burdensome and disproportionate to the risks posed by
the research to the participants [4].
Nearly all health and medical research involving
humans is generally required to undergo a review for ad-
herence to ethical standards and guidelines in terms of
the balance of benefits and harms, rights and well-being
of participants (hereafter ‘ethics review’). Where research
participation involves a considerable physical risk, psy-
chological risk or burden to participants, ethics reviews
are an important means of protecting the health and
well-being of research participants. However, some cat-
egories of ethics reviews have been criticised for imped-
ing or delaying research [5–7], imposing costs that do
not contribute to greater protection of research partici-
pants [8], being overly burdensome [9], and inconsistent
risk determinations for the same study protocol across
multiple sites [10–13].
The last of these seems to have been especially prob-
lematic in relatively simple studies, where the likelihood
of discomfort, harm or inconvenience to participants is
not expected to exceed that encountered in daily life, or
whilst undergoing routine examinations or tests [11].
For example, a low-risk survey of medical students
deemed exempt from further review by its home (United
States-based) institution nevertheless required further
reviews by 84 other Institutional Review Boards in
United States medical schools [14]; a minimal risk health
services research project required a full board review by
15 sites and was granted expedited review by two [15].
This variability can impose considerable costs – over 50
person-months costing $120,000 USD in the first case,
and 27 months costing $170,000 USD in the second.
The issue is not specific to the United States, as an Aus-
tralian multi-site study on the quality of hospital care re-
ported spending over $263,000 AUD in 1 year on costs
associated with the varying institutional consent pro-
cesses [16].
‘Proportional ethics review’ may be one way to help
mitigate this problem. Proportional review pins the level
of review and scrutiny to the level of perceived risk asso-
ciated with the proposed research project – research
projects that carry no or low risk receive no or minimal
review; projects which carry higher risk, conversely,
undergo more extensive review. The attractiveness of
this approach consists in its efficiency – “each applica-
tion would receive no more scrutiny than it needs” [17].
The implication of this approach is that certain types of
low or negligible risk human health/medical research
could be exempted entirely from ethics reviews. ‘Exemp-
tion from ethics review’ can include a range of ap-
proaches. For example, it could involve bypassing review
by an ethics committee completely before commencing
the research project, informing the committee of the
project (e.g. by submitting an exemption form) but not
submitting an application for review, or some form of
partial or expedited review (e.g. by a sub-committee of
the ethics committee or solely by its chair).
Comparisons between different countries’ approaches
to exempting from ethics reviews of low-risk human
health/medical research – that is, research that generally
falls on the minimal burden, intrusion or inconvenience
end of the research risk spectrum – may shed light into
each country’s individual practices as well as identify
possible solutions to problems [18–20]. Better under-
standing of the examples of exemptions of human
health/medical research from ethics review in different
jurisdictions may also help guide modification of review
processes and help reduce waste of researchers’ and eth-
ics committees’ time and resources when assessing low
risk research.
To increase understanding of these issues we have
attempted to identify explicit examples of exemptions of
low-risk human health/medical research from ethics re-
views in Australia, the United Kingdom, the United
States and the Netherlands.
Methods
For the purposes of this project, we considered ‘exempt
from ethics review’ to be those types or examples of re-
search that were explicitly identified as such. For ex-
ample, in the United Kingdom, this included research
projects that were exempted from a requirement to
undergo review by a National Health Service (NHS) re-
search ethics committee; in the United States, ‘exempt’
projects were those that fell outside the Code of Federal
Regulations Title 45: Public Welfare, part 46 (45 CFR
46). (In practice, these two approaches would be consid-
ered ‘bypassing ethics review altogether’ and ‘informing
the committee but not applying for ethics review’ end of
the spectrum).
Australia, the United Kingdom, the United States and
the Netherlands were selected as comparator countries
because of the anticipated breadth of examples, availabil-
ity of experts with knowledge of the key features of each
jurisdiction’s health and medical research milieu as well
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as its research ethics systems (SK, CP, ZH), and the
availability of documentation in English.
The analysis was document based. To identify exam-
ples or research project types that were ‘exempt from
ethics review’, we examined documents providing na-
tional guidance on research ethics in each country. We
focused on national level guidance to ensure comparabil-
ity. The analysed documents were the following:
1. Australia: National Health and Medical Research
Council National Statement on Ethical Conduct in
Human Research 2007 (Updated 2018) [21]
2. United Kingdom: NHS Governance Arrangements
for Research Ethics Committees: 2018 Edition” [22]
and NHS Standard Operating Procedures for
Research Ethics Committees version 7.3 (September
2018) [23]
3. United States: 45 CFR 46 section 104 [24] and
Department of Health and Human Services, Office
for Human Research Protections, Human Subject
Regulations Decision Charts [25]
4. Netherlands: Central Committee on Research
Involving Humans (CCMO), Your Research: Is it
Subject to WMO [Medical Research Involving
Human Subjects Act] or Not? [26]
One author (AMS) read all documents in full and
identified types and examples of human health/medical
research explicitly identified in those documents as be-
ing exempt from ethics review. A table was created with
a column for each country, and all identified exemptions
were listed in the table, creating as many rows as re-
quired (one for each exemption). These were then reor-
ganised, and categories of exemptions that were similar
or shared across countries were placed in the same row.
This was done iteratively, until no more similar categor-
ies of exemptions were identified. Where uncertainties
arose regarding interpretation or terminological differ-
ences regarding any of the exemptions, the expert on
that jurisdiction (SK, CP, ZH) was queried. Once uncer-
tainties were resolved, the final table with exemptions
was generated by two authors (AMS, PG).
Results
The overall results (Table 1) illustrate considerable vari-
ation in countries’ approaches to exempting research
Table 1 Examples and types of health and medical research exempted from ethics reviews
Exemption Australia United Kingdom United States of America Netherlands
Existing data/
specimen
Existing collection of data or
records that contain only non-
identifiable data
Previously collected,
non-identifiable tissue
samples
Secondary research use of
identifiable biospecimens
(subject to criteria)
Exempt
Questionnaire or
survey
Filling in a form, participating in
a street survey (where those are
no more than inconvenience)
Educational tests, survey
procedures (subject to
criteria)
Exempt, unless it imposes rules of
behaviour (e.g. required to be done
repeatedly) or topic is sensitive (e.g.
suicide, abortion)
Interviews Interview procedures
(subject to criteria)
Exempt, unless it imposes rules of
behaviour (e.g. required to be done
repeatedly) or topic is sensitive (e.g.
suicide, abortion)
Post-marketing
studies
Healthcare market
research conducted by
professional market
researchers
e.g. collecting data on adverse effects of
medicines already available on the
market
Evaluation of
public benefit or
service
programme
e.g. procedures for
obtaining benefits,
alternatives, changes in
payment levels
Randomised
controlled trials
May be exempt if meets the exemption
rule below (see ‘other’ category)
Research with
staff in their
professional role
Research involving NHS
staff acting in their
professional roles
Audit and
service
evaluation
a Audit and service
evaluation
Other
exemptions
“Giving up time to participate in
research” (example of an
inconvenience)
Medical/scientific research that does not
expose persons to treatment, or require
persons to follow certain behavioural
rules
a Dealt with outside of the National Statement (see below)
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from ethics review. Across all four countries, almost half
of the categories had some examples of exemptions.
Existing non-identifiable data and specimens were ex-
empt in all countries. Four categories – evaluation of
public benefit or service programme, randomised con-
trolled trials, research with staff in their professional
role, and audit and service evaluation – were exempted
by one country each. The Netherlands had the most ex-
tensive exemptions.
Australia
The National Health and Medical Research Council’s
National Statement on Ethical Conduct in Human Re-
search 2007 (Updated 2018) [21] identifies human health
and medical research that can be exempted from ethics
review in Australia.
Section 5.1.22 allows institutions to exempt from eth-
ics review research that is:
(1) Negligible risk research and
(2) Involves the use of existing collections of data or
records that contain only non-identifiable data
about human beings
Negligible risk is defined in s2.1.7 as research where
“any foreseeable risk is no more than inconvenience”. ‘In-
convenience’ is the lowest of the three types of risks
identified by the National Statement; ‘discomfort’ is clas-
sified as a higher level of risk, and ‘harm’ is classified
higher still. Inconvenience “may include filling in a form,
participating in a street survey, or giving up time to par-
ticipate in research” [21].
According to s 5.1.22, therefore, exempt research in
Australia is research that involves at most ‘inconveni-
ence’ (i.e. research that involves completing a form, par-
ticipating in a street survey, giving up time to take part
in research), and research involving existing data/records
on human beings who are non-identifiable.
It is worth emphasising that the National Health and
Medical Research Council (NHMRC) National State-
ment focuses on ‘research.’ Because quality assurance
and evaluation activities may not be considered research,
they are addressed by a separate NHMRC document
[27]. Because they commonly involve “minimal risk, bur-
den or inconvenience to their participants”, the ethics re-
view processes are not thought to be optimal, but rather
that “organisational oversight” ought to apply [27].
United Kingdom
The United Kingdom has the largest coordinated NHS
in the world. The NHS constitution commits the NHS
to “innovation and to the promotion, conduct and use of
research” [28]. This provides clear justification for the
use of audit, service development and research to ad-
vance both medical knowledge and standards of care.
Audit and service evaluation are sometimes differenti-
ated from research; whereas ‘research’ encompasses ac-
tivities aiming at creating new, generalisable knowledge,
‘audits’ review the current care practice or care delivery
and ‘quality improvement’ (sometimes also called service
evaluation) pilots new practices [11, 29]. Because both
audit and service evaluation are considered part of usual
professional practice in the NHS, they are exempt from
oversight processes that govern research – that is, they
do not require review by a research ethics committee
(REC) as any ethical concerns should be identified as in-
herent in clinical or professional ethics [30].
Research involving NHS staff is also exempt within the
NHS system. This decision was based on legal advice
that any ethics issues that arise (e.g. surrounding con-
sent, risks, etc.) are already covered by employment law
[22].
Research limited to work on material such as previ-
ously collected cells or tissues that are non-identifiable is
generally exempted from REC review [22].
Healthcare market research does not normally require
a REC review, as long as it is conducted by professional
market researchers and complies with the guidelines of
the British Healthcare Business Intelligence Association
[30].
Nevertheless, as a matter of law, any work in the
United Kingdom – whether audit, service evaluation or
staff research – that falls under definitions contained
within the Medicines for Human Use (Clinical Trials)
Regulations 2004, Medical Devices Regulations 2002,
Mental Capacity Act 2005, and Human Tissue Act 2004,
must be reviewed by a United Kingdom Ethics Commit-
tee Authority-authorised REC [22]. In addition to studies
requiring REC review by law, all other projects that have
been defined as research and involve NHS patients or fa-
cilities must be reviewed by a REC. For non-NHS work
(e.g. at universities, companies or with private patients),
the aforementioned acts and regulations remain applic-
able, and any relevant work must be reviewed by a
United Kingdom Ethics Committee Authority-
recognised committee although, on occasion, healthcare
research not subject to these acts may be conducted
with ethics reviews provided by university or other
RECs.
United States
Research conducted or supported by the United States
Department of Health and Human Services is regulated
by the United States Code of Federal Regulations. ‘Ex-
empt research’ is research for which there is no submis-
sion for ethics review; instead, an “exempt study
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submission form” is submitted to an Institutional Review
Board (IRB) [24, 25].
Research eligible for exemption under United States
regulation 45 CFR 46 (revised July 2018) includes sec-
ondary research uses of identifiable biospecimens as long
as at least one of four criteria are met, namely (1) the re-
search plan is publicly available; (2) the identity of hu-
man ‘subjects’ cannot be readily ascertained; (3) it
involves information collection and analysis for ‘health-
care operations’, ‘research’ or ‘public health activities
and purposes’; or (4) the research is being performed by
or on behalf of a federal department or agency using in-
formation generated or collected by the government for
non-research activities.
Research involving educational tests (e.g. cognitive,
diagnostic, aptitude), survey procedures, and interview
procedures is also exempt if at least one of three criteria
are met, namely (1) the identity of human ‘subjects’ can-
not be readily ascertained; (2) disclosure of responses
outside the research would not place ‘subjects’ at risk of
criminal or civil liability, or be damaging to financial
standing, employability, educational advancement or
reputation; or (3) identity of ‘subjects’ can be readily
ascertained and an IRB conducts a limited review.
Research designed to evaluate or improve public bene-
fit or service programmes (e.g. procedures for obtaining
benefits under these programmes, alternatives to those
programmes, changes in levels of payments for benefits
or services, etc.) is also considered exempt.
Although research may be categorised as ‘exempt’, it
may nevertheless be subject to IRB approval or review if,
for example, it involves prisoners, pregnant women, chil-
dren or members of other protected classes or vulner-
able groups. In addition to the regulations set forth at 45
CFR 46 with oversight by the Office for Human Re-
search Protections, research in the United States may
also be regulated by the Food and Drug Administration,
National Institutes of Health, and other sponsors or state
or local governments. Jurisdictional issues and sources
of funding may also play a role in the determinations of
exempt status.
Netherlands
In the Netherlands, medical/scientific research that ex-
poses participants to procedures/treatments, or requires
participants to follow rules of behaviour, falls under the
scope of the Medical Research Involving Human Sub-
jects Act (WMO) and must undergo review by an accre-
dited Medical Research Ethics Committee or the
CCMO.
Studies involving human participants are not subject
to the WMO if persons are not exposed to procedures/
treatment or are not required to follow a certain behav-
ioural strategy. For example, research is exempt if a
participant is not physically involved in the research and
only their previously collected data is being used. Retro-
spective research, such as file research or research with
residual tissue, is therefore considered exempt [26].
However, the Dutch government is currently preparing
legislation that introduces an obligatory review of sec-
ondary use of tissue for research to be carried out by the
same accredited Medical Research Ethics Committees.
In some cases, it may be unclear what research activ-
ities fall within or outside of the scope of the WMO.
Therefore, the CCMO has set up guidelines considering
the scope of the law. The guidelines make clear that a
study in which a participant provides a urine sample
only once is not subject to the WMO (i.e. that study is
considered exempt). However, if the participant were re-
quired to repeatedly provide urine samples over several
weeks, that research would fall within the scope of the
law (i.e. require ethics review) as the participant would
have to follow a specific behavioural strategy [26].
On the other hand, the CCMO offers an example of a
randomised controlled trial that would be exempt from
the requirement for ethics review, that of a study rando-
mising patients to the use of mattress A or mattress B in
a hospital. This would be exempt from ethics review as
it is not considered a change of normal hospital proce-
dures [26].
Research consisting of interviews or questionnaires
falls outside of the scope of the WMO and is exempt
from ethics review unless it imposes a rule of behaviour
(e.g. it needs to be conducted daily over several days).
However, if the topic is sensitive (e.g. it pertains to sui-
cide, mental illness, etc.) this research is no longer ex-
empt [31].
Post-marketing studies, such as those collecting data
on side effects of medication that is already available on
the market, are also considered exempt [31]. However,
this type of research is not completely free of assessing
its medical-ethical (and legal) aspects – guidelines (‘self-
regulation’) provide for a proper (i.e. lighter) review
system.
Discussion
All four countries exempt from ethics review at least
some types of human health and medical research. The
broadest set of exemptions exist in the Netherlands and
the narrowest in Australia. All countries exempt re-
search on existing data or specimens, provided they are
non-identifiable; three countries exempt questionnaire
or survey research, albeit subject to stipulated condi-
tions, for example, minimal inconvenience.
Historically, ethics review has been important to en-
sure an appropriate balance of potential benefits and
risks and informed consent for higher-risk research. Al-
though one of the most common exemptions is research
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involving non-identifiable existing data or specimens,
the issue of non-identifiability requires careful manage-
ment, as considerable risks may arise from re-
identification, e.g. in context of genetic studies [32].
Nevertheless, much low-risk research – for example,
surveys, quality improvement projects, clinical audits –
has been caught in the ethics assessment net, with differ-
ent nets in different countries, perhaps partly driven by
the lack of clear boundaries between them [6, 33].
This initial comparison of international variations in
research ethics reviews documents these variations but
explaining them confronts the challenges associated with
any international comparison – that is, difficulties in
comparing research regulation within differing health-
care systems and settings. These reflect varying sociocul-
tural values and differences in the histories that have
driven evolution of research ethics regulation and legis-
lation in each country. Moreover, although each of the
documents analysed here is a key national-level docu-
ment pertaining to ethical issues around human health
and medical research, they are not identical in scope. In-
evitably, therefore, the findings presented here are sim-
plified and omit some of the complexities of each
system. Including more countries in the comparison
would almost certainly have yielded evidence of yet
more diversity than that we have documented. The se-
lection of these particular countries was driven by prag-
matic considerations, including availability of expertise
and English-language documentation; however, it is
noteworthy that even this limited sample establishes
considerable variety in international practices.
The evidence of waste resulting from hyper-regulation
of clinical and health research that motivated this re-
search demands greater accountability to the public
among research regulators. Their work requires auditing
just as this is an expectation of other professionals.
The variations in exemptions from ‘full’ ethics review
we have identified suggest opportunities to extend docu-
mentation of international and intranational differences
and proposals for streamlining of ethics review pro-
cesses. Although innovation in the area of ethics review
may pose considerable challenge, some innovations in
this area have recently been implemented and described
[34–36]; for example, in a review of its research ethics
processes, Médecins Sans Frontières developed four in-
novative practices, namely (1) introduction of a policy
exempting a posteriori analysis of routinely collected
data; (2) the preapproval of ‘emergency’ protocols; (3)
general ethics approval of ‘routine’ surveys; and (4)
evaluating the impact of approved studies [36]. Never-
theless, the aforementioned criticisms of current prac-
tices in ethics reviews – that they impede research, fail
to protect participants, are burdensome and inconsistent
across sites – coupled with the calls to investigate and
implement ‘alternative’ models of review, make clear that
further innovation and evaluation is still much needed
[36, 37].
It would be helpful if the bodies in charge of providing
guidance on research ethics could provide clear and
transparent rationale underpinning each exemption. The
Netherlands provides an excellent example of this, expli-
citly stipulating that exposing participants to treatment,
or requiring them to follow behavioural rules, are the
determinants of whether research requires ethics review.
Clarity and transparency in the rationales underpinning
exemptions could assist research ethics committee
decision-making, potentially freeing up the time and re-
sources of both ethics committee members (to focus on
higher risk projects) and researchers (to conduct their
research).
Exemptions identified here could also be considered
by countries that do not presently exempt these types of
research. For example, the United Kingdom’s exemption
of research involving NHS staff acting in their profes-
sional roles – or more broadly, research involving
healthcare providers and experts querying their expertise
– could be considered for adoption in other countries.
For example, our identification of the paucity of exemp-
tions in Australia as compared to the other countries
has so far spurred two initiatives – a petition to the Aus-
tralian Government to seek a national inquiry to stream-
line and improve research ethics and governance in
Australia [38], and a national survey (recently com-
pleted) of researchers and ethics committee members.
The survey helped to identify the extent to which
current research ethics rules lead researchers to modify
or forego research projects as well as the reasons for po-
tentially exempting, in Australia, some of the exemptions
identified here. The survey results will be provided to
the NHMRC for its next planned revision of the Na-
tional Statement on Ethical Conduct in Human
Research.
Finally, where a full exemption is considered inappro-
priate, there is a wide range of options that could de-
crease some of the burden of ethics reviews, including
partial exemption or expedited review. These options are
often identified in ethics guidance documents (e.g.
NHMRC) but they remain underused, as ethics review
practices are more demanding than that required by reg-
ulations [5]. One example of this ‘partial’ approach is the
Proportionate Review process used by the United King-
dom’s Health Research Authority [39], which has re-
duced review times for relevant projects by a third [40].
Eligible for Proportionate Review are those studies that
pose minimal risk, burden or intrusion to participants,
including research with anonymously collected data or
tissue, questionnaires or interviews that do not include
highly sensitive areas, or research surveying the safety or
Scott et al. Health Research Policy and Systems           (2020) 18:11 Page 6 of 8
efficacy of established non-drug treatments, and exclud-
ing research involving prisoners, adults lacking capacity
to consent or clinical trials of investigational medicinal
products [39]. Studies that are judged appropriate for
Proportionate Review using the No Material Ethical Is-
sues Tool can be reviewed remotely by three REC mem-
bers (with at least 6 months service on a research ethics
committee) with the aim of providing a decision to the
researchers within 21 calendar days, although the Health
Research Authority has recently piloted reducing this
time to 13 working days [40]. RECs completing a pro-
portionate review are able to promote a proportionate
review project to full review if they think there are sig-
nificant ethical issues. Consultations are ongoing as to
whether this review process could be expanded to a
wider range of projects.
Conclusion
Given the considerable costs and burdens on researchers
and ethics committees, it would seem worthwhile to de-
velop and provide clearer guidance on exemptions from
full ethics review, illustrated with examples derived from
multiple jurisdictions, with transparent underpinning ra-
tionales. We hope the examples provided here may be a
motivator to free the negligible and low risk research
from the “shadow of protracted ethics review” [33].
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